These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36697456)
1. Iterated cross validation method for prediction of survival in diffuse large B-cell lymphoma for small size dataset. Chang CC; Chen CH; Hsieh JG; Jeng JH Sci Rep; 2023 Jan; 13(1):1438. PubMed ID: 36697456 [TBL] [Abstract][Full Text] [Related]
2. Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Chang CC; Cho SF; Tu HP; Lin CY; Chuang YW; Chang SM; Hsu WL; Huang YF Medicine (Baltimore); 2017 Nov; 96(45):e8655. PubMed ID: 29137104 [TBL] [Abstract][Full Text] [Related]
3. Interim 18F-FDG PET/CT and BCL2 for predicting the prognosis of patients with diffuse large B-cell lymphoma in the rituximab era. Jiang M; Chen P; Ruan X; Xu W; Li T; Wu L; Zhou W; Wu H; Wang Q Nucl Med Commun; 2018 Feb; 39(2):147-153. PubMed ID: 29189488 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
7. [Values of Different Evaluation Criteria of Interim Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288 [TBL] [Abstract][Full Text] [Related]
8. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558 [TBL] [Abstract][Full Text] [Related]
9. Radiomics signature from [ Jiang C; Huang X; Li A; Teng Y; Ding C; Chen J; Xu J; Zhou Z Eur Radiol; 2022 Aug; 32(8):5730-5741. PubMed ID: 35298676 [TBL] [Abstract][Full Text] [Related]
10. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [ Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227 [TBL] [Abstract][Full Text] [Related]
11. Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings. Kong Y; Qu L; Li Y; Liu D; Lv X; Han J Medicine (Baltimore); 2016 Feb; 95(6):e2808. PubMed ID: 26871850 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma. Chang CC; Cho SF; Chuang YW; Lin CY; Huang YF; Tyan YC Medicine (Baltimore); 2018 Jan; 97(2):e9513. PubMed ID: 29480842 [TBL] [Abstract][Full Text] [Related]
13. Value of Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996 [TBL] [Abstract][Full Text] [Related]
14. Different predictive values of interim Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the prognostic value of the metabolic volumetric parameters calculated with Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Rodríguez Carrillo JL; Dotor de Lama A; Navarro Matilla MB; Mitjavila Casanovas M Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):215-222. PubMed ID: 35469793 [TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
17. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Frood R; Burton C; Tsoumpas C; Frangi AF; Gleeson F; Patel C; Scarsbrook A Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3198-3220. PubMed ID: 33604689 [TBL] [Abstract][Full Text] [Related]
18. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359 [TBL] [Abstract][Full Text] [Related]
19. The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. Choi JH; Lim I; Byun BH; Kim BI; Choi CW; Kang HJ; Shin DY; Lim SM PLoS One; 2022; 17(9):e0273839. PubMed ID: 36156599 [TBL] [Abstract][Full Text] [Related]
20. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]